A Study to Evaluate Vinorelbine Plus Capecitabine Combined With Trastuzumab for HER2 Positive Patients Following Neoadjuvant Chemotherapy
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy
Breast Cancer
DRUG: Vinorelbine|DRUG: Capecitabine
Disease free survival, The length of time after primary treatment for a cancer ends that the patient survives without any signs or symptoms of that cancer, 3 year
Recurrence free survival, Recurrence free survival is calculated from surgery to the first recurrence, 3 year|Distant disease free survival, Distant disease free survival is calculated from surgery to the first distant metastasis., 3 year|Overall survival, Overall survival is calculated from randomization to death from any cause., 5=3 year
This study aims to evaluate vinorelbine plus capecitabine combined with trastuzumab versus trastuzumab alone as the adjuvant Treatment of HER2 positive patients following neoadjuvant chemotherapy